Reviewing Icon (NASDAQ:ICLR) & OmniAb (NASDAQ:OABI)

OmniAb (NASDAQ:OABI – Get Free Report) and Icon (NASDAQ:ICLR – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares OmniAb and Icon”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OmniAb $18.67 million 36.41 -$64.78 million ($0.34) -13.71
Icon $8.25 billion 1.73 $229.34 million $5.81 32.14

Icon has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for OmniAb and Icon, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OmniAb 1 0 3 0 2.50
Icon 1 9 9 1 2.50

OmniAb presently has a consensus price target of $11.50, indicating a potential upside of 146.78%. Icon has a consensus price target of $213.76, indicating a potential upside of 14.49%. Given OmniAb’s higher possible upside, equities analysts clearly believe OmniAb is more favorable than Icon.

Volatility & Risk

OmniAb has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Icon has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Insider & Institutional Ownership

72.1% of OmniAb shares are owned by institutional investors. Comparatively, 95.6% of Icon shares are owned by institutional investors. 9.8% of OmniAb shares are owned by company insiders. Comparatively, 44.0% of Icon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares OmniAb and Icon’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OmniAb -108.11% -16.74% -14.79%
Icon 5.45% 7.73% 4.39%

Summary

Icon beats OmniAb on 12 of the 14 factors compared between the two stocks.

About OmniAb

(Get Free Report)

OmniAb, Inc. is a biotechnology company that develops antibody discovery technologies for use in creating therapeutic medicines. It works with pharmaceutical and biotechnology companies to identify and advance antibody candidates for potential drug development. Its platform includes genetically engineered animals that can produce antibodies with human characteristics, along with related discovery and screening technologies. These tools are designed to help partners find antibodies for a range of therapeutic targets and applications.

About Icon

(Get Free Report)

ICON plc is a global contract research organization (CRO) that provides outsourced development services to pharmaceutical, biotechnology, medical device and government organizations. Its work supports the development of medicines and other healthcare products from early research through clinical trials and regulatory submission. The company’s services include clinical trial design and management, data management and biostatistics, regulatory support, laboratory services, medical imaging and patient recruitment.

Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.